Εργαστήριο Φαρμακευτικής Βιοτεχνολογίας και Μοριακής Διαγνωστικής

ΥΠΟΔΟΧΗ ΦΟΙΤΗΤΩΝ/ΤΡΙΩΝ

Ώρες γραφείου: Τρίτη 13:00-16:00 μ.μ
Τετάρτη 12:00-14:00 μ.μ

Συνεργαζόμενο μέλος ΔΕΠ:
Γεώργιος Παμπαλάκης, Αναπληρωτής Καθηγητής, Φαρμακευτική ΑΠΘ
Επιστημονικός Υπεύθυνος Έργου ΕΛΙΔΕΚ K6PD-1876 (80596 ΕΛΚΕ Πανεπιστημίου Πατρών)

Μεταδιδάκτορες
Ελένη Ζήνγκου
Γκόλφω Κορδοπάτη

Υποψήφιοι Διδάκτορες
Ευάγγελος Μπισύρης
Νικόλα Χουρί

Μεταπτυχιακοί Φοιτητές
Ελένη Τσιαούση
Χριστίνα Γιαννακοπούλου
Κυριακή Ευαγγελάτου

Διπλωματικοί Φοιτητές
Μαρία Σαρρή
Ozgkiour Antoula Chalil
Νίκος Αντωνόπουλος

ΙΑΝΟΥΑΡΙΟΣ 2022 - ΝΕΑ ΑΠΟ ΤΗΝ ΈΡΕΥΝΑ ΜΑΣ

ΧΡΗΜΑΤΟΔΟΤΗΣΗ ΑΠΟ ΗΠΑ ΓΙΑ ΕΡΕΥΝΑ ΣΤΗΝ ΝΟΣΟ ALZHEIMER / PROJECT FUNDED BY THE ALZHEIMER’S FOUNDATION (Chicago, IL, USA)

ΝΕΑ - Φεβρουάριος 2018

Χρηματοδοτούμενα Ερευνητικά Προγράμματα

Πρόσφατα εγκρίθηκαν για χρηματοδότηση τρία (3) νέα ερευνητικά προγράμματα, τα οποία θα υλοποιηθούν από την Ομάδα Φαρμακευτικής Βιοτεχνολογίας και Μοριακής Διαγνωστικής-Εργαστήριο Φαρμακογνωσίας του Τμήματος Φαρμακευτικής, σε συνεργασία με άλλα ΑΕΙ και Ερευνητικά Ιδρύματα. Τα εγκριθέντα έργα είναι:

[1] ΔΡΑΣΗ «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ» (ΕΥΔΕ ΕΤΑΚ - ΕΥΔ ΕΠΑνΕΚ ΕΣΠΑ 2014-2020)

Τίτλος: “Νανογαλακτώματα φυτικών ελαιών με ενυδατικές και εντομοαπωθητικές ιδιότητες”

Ακρωνύμιο: QFytoTera και Κωδικό: Τ1ΕΔΚ-00996

Επιστημονική Υπεύθυνος: Γεωργία Σωτηροπούλου

Τίτλος στα Αγγλικά: "Nanoemulsions of plant oils with moisturizing and insect repellent properties "

[2] ΔΡΑΣΗ «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ» (ΕΥΔΕ ΕΤΑΚ - ΕΥΔ ΕΠΑνΕΚ ΕΣΠΑ 2014-2020)

Τίτλος: Ανάπτυξη προηγμένης τεχνολογίας βιοδεικτών για την διαφοροδιάγνωση της νόσου Parkinson

Ακρωνύμιο: BIOLUMIPD και Κωδικό: Τ1ΕΔΚ-03884

Επιστημονική Υπεύθυνος: Γεωργία Σωτηροπούλου

Τίτλος στα Αγγλικά: "Development of improved biomarker technologies for the discriminative diagnosis of Parkinson disease "

[3] 1η Προκήρυξη ερευνητικών έργων ΕΛΙΔΕΚ για την Ενίσχυση Μεταδιδακτόρων Ερευνητών/τριών

Τίτλος: “α-synuclein prion-like particles: in vivo turnover and infectivity”

Ακρωνύμιο: K6PD και Κωδικό: 1876

Επιστημονικός Υπεύθυνος: Γεώργιος Παμπαλάκης, Επίκουρος Καθηγητής

Θεματική περιοχή: Life sciences (Medical and Health Sciences), Natural Sciences

Περίληψη στα Ελληνικά

ΆΛΛΑ Χρηματοδοτούμενα Ερευνητικά Προγράμματα (εν εξελίξει)

[4] ERA-NET/E-Rare-3 (2016-2019): Joint Translational Call (2015) for "European Research Projects on Rare Diseases"

Τίτλος: "Ιχνηλατώντας τις ανεξερεύνητες πλευρές της νόσου PSD- Στόχευση της επιδερμικής πρωτεόλυσης για θεραπεία"

Ακρωνύμιο: Propekal5 και Κωδικό: 57670000

Επιστημονική Υπεύθυνος και Συντονίστρια Ευρωπαϊκού Consortium: Γεωργία Σωτηροπούλου

Τίτλος στα Αγγλικά: "Tracing the untackled facets of Peeling Skin Disease - Targeting epidermal proteolysis for treatment"

ΕΚΠΑΙΔΕΥΤΙΚΟ VIDEO TNK-tPA: Ανάπτυξη και κλινική χρήση

Current/Recent Collaborations

Alain Hovnanian, MD, PhD, Professor and Head
INSERM UMR S1164 IHU Imagine-Institut des maladies génétiques-Université Paris Descartes, Paris, FRANCE
URL: http://www.genegraft.eu/main-investigators

Eleftherios P. Diamandis MD, PhD, FRCP(C), FRSC, Professor
Hold'em for Life Chair in Prostate Cancer Biomarkers, Head of Clinical Biochemistry, Mount Sinai Hospital and University Health Network Professor and Head, Division of Clinical Biochemistry,
Dept. of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CANADA
URL: http://sites.utoronto.ca/acdclab
Kostas Vekrellis, Researcher B’
Division of Basic Neurosciences, Biomedical Research Foundation, Academy of Athens, Athens, GREECE URL: http://www.bioacademy.gr/faculty-details/HMw/kostas
AND Visiting Professor (2011-present)
University of Oxford, Medical School, Department of Experimental Medicine, Radcliffe Department of Medicine, Oxford, UK
Oliver Schilling, PhD, Group Leader, ERC Awardee
Emmy-Noether Research Fellow, Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, GERMANY
URL: http://www.sgbm.unifreiburg.de/index.php?option=com_zooprofiles&task=userProfile&user=6585
Guy Serre, MD, PhD, Professor, Directeur
Unité Différenciation Epidermique et Autoimmunité Rhumatoïde (UMR 5165), UDEAR - UMR 5165 CNRS, 1056 INSERM, Université de Toulouse, Hôpital PURPAN, Place du Dr Baylac TSA 40031, Toulouse, FRANCE
URL: http://www.udear.cnrs.fr/
Nathalie Jonca, Professor
CNRS UMR 5165 - INSERM U1056 - Toulouse III University, CHU Purpan, Place du Dr Baylac - TSA 40031, Toulouse, FRANCE
URL: http://www.e2brn.eu/members/jonca.html
Andras Nagy, Professor and Head and Dr. Iacovos Michael
Department of Molecular Genetics, University of Toronto and Mount Sinai Hospital and Samuel Lunenfeld Research Institute, Toronto, Ontario, CANADA
URLs: http://www.mshri.on.ca/nagy/
http://www.phenogenomics.ca/transgenics/links.html and http://www.lunenfeld.ca/researchers/nagy
George M Yousef, MD, PhD, FRCPC (Path), MSc, MBBCh, Professor
Department of Laboratory Medicine, St. Michael's Hospital and
Department of Laboratory Medicine and Pathobiology, University of Toronto, CANADA
URL: http://www.stmichaelshospital.com/research/profile.php?id=yousef
Dimitra Kiritsi, Assistant Professor, MD, FEBDV
Universitaetsklinikum, Klinik für Dermatologie und Venerologie
University of Freiburg, Freiburg, Germany URL: https://www.uniklinik-freiburg.de/hautklinik/
Evi S. Lianidou, Professor
Laboratory of Analytical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Department of Chemistry, University of Athens, Greece
URL: http://en.actc-lab.chem.uoa.gr/
Vassileios Zoumpourlis, Researcher A’
Biomedical Applications Unit, Institute of Biological Research and Biotechnology. National Hellenic Research Foundation, Athens, Greece
URL: http://www.eie.gr/nhrf/institutes/ibrb/serviceunits/bau-en.html

Earlier Collaborations:

Ruth Sager, Head at DFCI, Professor, Member of the National Academy of Sciences USA, and the Academy of Sciences and Arts USA Division of Cancer Genetics, Dana-Farber Cancer Institute (DFCI), Department of Genetics and Microbiology, Harvard Medical School, Boston, MA, USA

Arthur B. Pardee, Head at DFCI, Professor, Member of the National Academy of Sciences USA, and the National Academy of Sciences and Arts USA Division of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
Bonnie F. Sloane, Professor and Chair Department of Pharmacology, Wayne State Medical School, Detroit, MI, USA
Fransesc X. Aviles, Professor and Chair Institut de Biologia Fonamental and Departament de Bioquimica Universitat Autonoma de Barcelona, Bellaterra (Barcelona), SPAIN
Antonia Vlahou, Staff Research Scientist - Professor Level Proteomics Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, GREECE
Aristotelis Chatziioannou, Researcher B’ Metabolic Engineering–Bioinformatics Programme, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, GREECE
Vassilis Georgoulias and Dimitris Mavroudis, Professors and Head Laboratory of Tumor Cell Biology, Medical School, University of Crete, GREECE

News

GROUP LEADER

Sotiropoulou Georgiou, Professor
and Affiliated Investigator, Biomedical Research Foundation, Academy of Athens (2015)
and Visiting Professor, Imagine Institute, INSERM UMR 1163, University Hospital Institute, Université René Descartes Paris 5-Sorbonne Paris Cité, Paris, France (2014)

Public Profiles
• Google Scholar http://scholar.google.com/citations?user=Rlk1ntkAAAAJ&hl=el&oi=ao
• ResearchGate https://www.researchgate.net/profile/Georgia_Sotiropoulou
• LinkedIn https://www.linkedin.com/pub/georgia-sotiropoulou/91/887/628

GROUP MEMBERS

ΕΙΣΑΓΩΓΗ

Η Ομάδα Φαρμακευτικής Βιοτεχνολογίας και Μοριακής Διαγνωστικής εφαρμόζει βιοτεχνολογικές τεχνικές και μεθοδολογίες με σκοπό:

την κλωνοποίηση, μεταφορά και μελέτη της λειτουργίας γονιδίων που ενέχονται σε ασθένειες και συνιστούν δυνητικούς μοριακούς στόχους για ανάπτυξη φαρμάκων και μοριακών διαγνωστικών, όπως πχ η ανθρώπινη καλλικρεΐνη 6 ή KLK6 (Σχήμα) που αποτελεί θεραπευτικό στόχο για νευροεκφυλιστικές ασθένειες του ΚΝΣ.
την ταυτοποίηση και αξιολόγηση δυνητικών φαρμακολογικών στόχων με χρήση διαγονιδιακών ζωικών προτύπων.
την παραγωγή και βελτίωση με γενετική μηχανική των ιδιοτήτων ανασυνδυασμένων πρωτεϊνών φαρμακολογικού ενδιαφέροντος.
τη μελέτη των πρωτεολυτικών ενζύμων και ενδογενών αναστολέων τους: (1) στη γένεση και μετάσταση νεοπλασματικών όγκων, (2) σε φλεγμονώδεις ασθένειες του δέρματος που χαρακτηρίζονται από υπεραποφολίδωση και (3) στη νόσο του Parkinson.
την ποσοτική μέτρηση της γονιδιακής έκφρασης σε βιολογικά και κλινικά δείγματα.
την ανάπτυξη μοριακών διαγνωστικών που στηρίζονται σε DNA (πχ gene isoforms, μεθυλίωση DNA), RNA και πρωτεΐνες.
την ταυτοποίηση νεοφανών βιολογικών δεικτών στο περιφερικό αίμα για τη διάγνωση/πρόγνωση/σταδιοποίηση καρκίνου, καθώς και για την παρακολούθηση της ανταπόκρισης στη φαρμακοθεραπεία, και ποσοτική αξιολόγηση της ελάχιστης υπολειπόμενης νόσου.
τη μελέτη μοριακών μηχανισμών δράσης των φαρμάκων και ανάπτυξης ανθεκτικότητας στη φαρμακοθεραπεία.

Παραγωγή ενζυμικά δραστικής ανασυνδυασμένης KLK6, μελέτη του μηχανισμού ενεργοποίησης, και σταθεροποίηση της ενζυμικής δράσης με κατευθυνόμενη μεταλλαξιγένεση1.

Aνάλυση της τριτοταγούς δομής της πρωτεάσης proKLK6 με κρυσταλλογραφία περίθλασης ακτίνων Χ με όριο ευκρίνειας 1.7 Ǻ (PDB:1GVL)2.

Bayés A, Tsetsenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Biol Chem 385: 517-524, 2004 and
Gomis-Ruth FX, Bayes A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Vigellas V, Avillés FX, Coll M. J Biol Chem 277: 27273-27281, 2002

ONGOING RESEARCH PROJECTS

KLK5 drug target in skin

Book Chapter

Pharmacological targeting of the human tissue kallikrein-related peptidases.
Pampalakis G, Sotiropoulou G. (2012) In "Proteinases as Drug Targets", pp 199-228. Edited by Ben M. Dunn, Royal Society of Chemistry (RSC), RSC Drug Discovery, UK, RSC Publishing.

RESEARCH HIGHLIGHTS

MOUSE MODELS

Cancer models
Transgenic mouse models

ONGOING RESEARCH PROJECTS

SKIN DISEASES: Unraveling the roles of KLK proteases in overdesquamating and inflammatory skin pathologies characterized by defective epidermal barrier. Rare skin syndromes: Proof-of-principle for pharmacological targeting
PARKINSON DISEASE: Investigating proteolytic pathways for pharmacological targeting KLK proteases in cancer development and progression
CANCER: KLK proteases in cancer development and progression
VENOMICS: Mining snake venoms for novel pharmaceutical proteins

Current/Recent Funding

ERA-NET/E-Rare-3: Joint Translational Call (2015) for "European Research Projects on Rare Diseases". Project Title: "Tracing the untackled facets of Peeling Skin Disease-Targeting epidermal proteolysis for treatment" (Propekal5) [2015-2018, PI: GSotiropoulou] Total/Partner 1 Budget: €469,197 / €100,000
Europa Nostra2014; Greece-France Bilateral Cooperation Project 2013-2015. Project Title: "Integration of novel mouse models to advance understanding of epidermal proteolysis in rare genetic skin diseases such as the Netherton Syndrome-Basic and translational aspects" [ERADISK5, PI: GSotiropoulou] Budget: €30,000
Parkinson's Disease Foundation (PDF), International Research Grants Program (IRGP), NY, USA; Project Title: "Novel insights into the properties and fate of naturally secreted alpha-synuclein" [2014-2016, PI: GS] Budget: $165,000
2013 Fondation Santé Grants: "Is KLK6 protease the eluded regulator of extracellular α-synuclein?" [2013-2015, PI: GSotiropoulou] Budget: €40,000
Excellence Postdoctoral Grants (LS4-2139, Skink5) "Delineation of KLK5-mediated proteolytic pathways in skin desquamation" [2011-2014, PI: GSotiropoulou] Budget: €150,000

Current Research Interests

Molecular mechanisms underlying cancer development, invasion and metastasis-Identification of genes/proteins for targeted pharmaceutical compounds and/or molecular diagnostics.
Proteases and protease inhibitors (proteins/peptides, LMW/synthetic, aptamers).
Kallikrein-related proteases (KLKs).
Proteolytic pathways in normal physiology and disease states (skin overdesquamation and inflammation, α-synuclein processing, neoplastic progression).
Animal models for preclinical testing of pharmaceutical compounds.
Production and engineering of recombinant proteins of pharmacological interest.

Organization Of Meetings - Conferences - Workshops

5th General Meeting of the International Proteolysis Society (IPS2007) Conference and Cultural Center, University of Patras, 20-24 October 2007 >530 international participants; Chair: Georgia Sotiropoulou Αφίσα Συνεδρίου
Satellite Postgraduate Course on «Proteomics: Μethodologies and Αpplications»
Satellite Postgraduate Course on «Bioinformatics-Computational Methods in Biological Data Mining»
Satellite Postgraduate Course on «Enzyme Mechanisms and Kinetics» 19-20 October 2007, Department of Pharmacy, University of Patras

PATENTS

Sotiropoulou G, Pampalakis G, Bissyris E. (2018) “Theranostic inhibitors and activity-based probes for the KLK7 protease” Patent Application Nr: 2018010052 και ημερομηνία 16/11/2018.

Hovnanian A, Sotiropoulou G, Pampalakis G, Furio L. (2014) "Methods and pharmaceutical compositions for the treatment of Netherton syndrome". Application Nr: EP14153629.2 (03 Feb 2014), Priority date: 2014-02-03; Filing date: 2015-02-02; Publication date: 2015-08-06, WO2015114144A1, https://patents.google.com/patent/WO2015114144A1/en?q=klk5&q=inhibitors

Anisowicz A, Sager R, Sotiropoulou G. (1998) “Human protease M, a novel serine protease, and its cDNA sequence and diagnostic and therapeutic uses”. PCT Int. Patent, WO 98/11238, 1-92.

Sotiropoulou G, Anisowicz A, Sager R. (1997) “Human cystatin M cDNA sequence, recombinant vector, gene regulation in tumor, and cancer diagnosis and therapy”. PCT Int. Patent, WO 97/14797, 1-67.

SELECTED PUBLICATIONS

Zingkou E, Pampalakis G, Charla E, Nauroy P, Kiritsi D, Sotiropoulou G.* (2019) "A proinflammatory role of KLK6 protease in Netherton syndrome. J Derm Sci in press
Pampalakis G, Zingkou E, Sidiropoulos KG, Diamandis EP, Zoumpourlis V, Yousef GM, Sotiropoulou G. (2019) Biochemical pathways mediated by KLK6 protease in breast cancer. Mol Oncol 2019 Apr 13. doi: 10.1002/1878-0261.12493. [Epub ahead of print]
Zingkou E, Pampalakis G, Kiritsi D, Valari M, Jonca N, Sotiropoulou G. (2019) Activography reveals aberrant proteolysis in desquamating diseases of differing backgrounds. Exp Dermatol 28: 86-89. doi: 10.1111/exd.13832.
Khoury N, Zingkou E, Pampalakis G, Sofopoulos M, Zoumpourlis V, Sotiropoulou G. (2018) KLK6 protease accelerates skin tumor formation and progression. Carcinogenesis 39: 1529-1536. doi: 10.1093/carcin/bgy110.
Pampalakis G, Zingkou E, Sotiropoulou G. (2018) KLK5, a novel potential suppressor of vaginal carcinogenesis. Biol Chem 399: 1107-1111.
Devetzi M, Goulielmaki M, Khoury N, Spandidos DA, Sotiropoulou G, Christodoulou I, Zoumpourlis V. (2018) Genetically modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1) based targeted therapy (Review). Int J Mol Med 41: 1177-1186.
Pampalakis G, Sotiropoulou G. (2017) Insights into the regulation of proteolytic pathways in skin differentiation. Br J Dermatol 176: 1433-1434.
Pampalakis G, Zingkou E, Vekrellis K, Sotiropoulou G. (2017) “Activography”: a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ. Chem Commun (Camb) 53: 3246-3248.
Pampalakis G, Kiritsi D, Zingkou E, Valari M, Sotiropoulou G. (2017) Enhanced proteolytic activities in Acral Peeling Skin Syndrome: A role of transglutaminase 5 in epidermal homeostasis. J Invest Dermatol 137: 1808-1811.
Devetzi M, Goulielmaki M, Khoury N, Spandidos DA, Sotiropoulou G, Christodoulou I, Zoumpourlis V. (2018) Genetically modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1) based targeted therapy (Review). Int J Mol Med 41: 1177-1186.
Pampalakis G, Sykioti V-S, Ximerakis M, Stefanakou-Kalakou I, Melki R, Vekrellis K, Sotiropoulou G. (2016) KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget 8: 14502-14515.
Sidiropoulos KG, Ding Q, Pampalakis G, White NMA, Boulos P, Sotiropoulou G, Yousef GM. (2016) KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. Mol Oncol 10: 993-1007.
Furio L, Pampalakis G , Michael IP, Nagy A, Sotiropoul ou G*, Hovnanian A.* (2015) Elimination of KLK5 reverses the hallmarks of Netherton syndrome. PLoS Genet 2015 Sep 21;11(9):e1005389. http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005389
Pampalakis G, Politi AL, Papanastasiou A, Sotiropoulou G. (2015) Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - A new pool of biomarkers. Genes Cancer in press.
Pasic MD, Sotiropoulou G, Yousef GM. (2015) The miRNA-Kallikrein interactions: adding a new dimension. Cell Cycle 14: 691-692.
Sidiropoulos KG, White NMA, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, Sotiropoulou G, Yousef GM. (2014) Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience 1: 709-724.
Ximerakis M, Pampalakis G, Roumeliotis TI, Sykioti V-S, Garbis SD, Stefanis L, Sotiropoulou G, Vekrellis K. (2014) Resistance of naturally secreted alpha-synuclein to proteolysis. FASEB J 28: 3146-3158.
Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G.* (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget 5: 2390-2403.
Sotiropoulou G, Pampalakis G. (2012) Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 33: 623-634.
Sotiropoulou G, Pampalakis G, Prosnikli E, Evangelatos GP, Livaniou E. (2012) Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6. Chem Cent J 6: 148.
Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E. (2012) CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem 46: 235-240
Kapasa M, Vlachakis D, Kostadima M, Sotiropoulou G, Kossida S. (2012) Towards the elucidation of the regulatory network guiding the insulin producing cells' differentiation. Genomics 100: 212-221.
Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES. (2011) DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 57: 1169-1177.
Arnold S, Pampalakis G, Kantiotou K, Silva D, Cortez C, Missailidis S, Sotiropoulou G. (2011) One round of SELEX for the generation of DNA aptamers directed against KLK6. Biol Chem 393: 343-353.
Pavlopoulou A, Pampalakis G, Michalopoulos I, Sotiropoulou G. (2010) Reconstruction of the evolutionary history of tissue kallikreins. PLoS ONE 5: e13781-13781.
Lianidou ES, Mavroudis D, Sotiropoulou G, Aggelaki S, Pantel K. (2010) What’s new on Circulating Tumor Cells? A meeting report. Breast Cancer Res 12: 307-311.
Sotiropoulou G, Pampalakis G. (2010) Evolving concepts of tissue kallikrein-related peptidases as bridges of immune function and proteolytic destruction of extracellular matrix. Biol Chem 391: 321-331.
Sotiropoulou G, Pampalakis G, Diamandis EP. (2009) Functional roles of human kallikrein-related peptidases. J Biol Chem 284: 32989-32994. http://www.jbc.org/site/thematics/proteolytic_enzymes/
Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G.(2010) Down-regulation of Dicer mRNA in ovarian cancer tissues provides a new potential biomarker. Clin Biochem 43: 324-327
Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G. (2009) Down-regulation of Dicer expression in ovarian cancer tissues. Clin. Biochem. 2009 Sep 24. [Epub ahead of print]
Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. (2009) A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 69: 3779-3787.
Sotiropoulou G, Pampalakis G, Lianidou ES, Mourelatos Z. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15: 1443-1461.
Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. (2009) Methylation of cystatin M promoter in breast cancer is associated with unfavorable prognosis. Int. J. Cancer, in press
Sotiropoulou G , Sommerhoff CP. (2008) Highlight on advances in proteolysis research. Biol. Chem. 389: 967-969.
Pampalakis G, Scorilas A, Sotiropoulou G. (2008) Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. Clin. Biochem. 41: 591-597
Pampalakis G, Arampatzidou M, Amoutzias G, Kossida S, Sotiropoulou G. (2007) Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates. Comput. Biol. Chem. 1776: 22-31
Borgoño CA, Gavigan JA, Alves J, Bowles B, Harris JL, Sotiropoulou G, Diamandis EP (2007) Defining the extended substrate specificity of kallikrein 1-related peptidases. Biol. Chem. 388: 1215-1225.
Pampalakis G,Sotiropoulou G. (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. BBA Reviews on Cancer 1776: 22-31.
Borgoňo C, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Blaber M, Diamandis EP. (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation: Regulation by lympho-epithelial Kazal-type inhibitor and digestion of desmoglein 1. J. Biol. Chem. 282: 3640-3652.
Shaw JLV, Grass L, Sotiropoulou G, Diamandis EP. (2006) Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin. Biochem. 40: 104-110.
Borgoňo C, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Blaber M, Diamandis EP. (2006) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation: Regulation by lympho-epithelial Kazal-type inhibitor and digestion of desmoglein 1. Journal of Biological Chemistry Dec 11 [Epub ahead of print]
Shaw JLV, Grass L, Sotiropoulou G, Diamandis EP. (2006) Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clinical Biochemistry 40: 104-110. Epub 2006 Aug 25
Pampalakis G, Diamandis EP and Sotiropoulou G. (2006) The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biological Chemistry, 387: 795-799.
Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, Diamandis EP. (2006) Involvement of human kallikrein 5 (hK5) in proteolytic cascade pathway culminating in seminal plasma liquefaction and prostate cancer progression. Journal of Biological Chemistry 281: 12743-12750.
Lundwall Ǻ, Band V, Blaber M, Clements J, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman U-H, Stephan C, Talieri M, Yousef GM. (2006) A comprehensive nomenclature for serine proteases with homology to the tissue kallikrein. Biological Chemistry, 387: 637-641.
Pampalakis G, Sotiropoulou G. (2006) Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biological Chemistry, 387: 773-782.
Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D, Diamandis EP (2005) Down-Regulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumor Biology 26: 324-336.
Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP. (2005) Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clinical Chemistry 51: 1432-1442.
Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. Journal of Biological Chemistry 280: 14628-14635.
Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biology 25: 193-199.
Pampalakis G, Kurlender L, Diamandis EP, Sotiropoulou G. (2004) Cloning and characterization of novel isoforms of the human kallikrein 6 gene. Biochemical and Biophysical Research Communications 320: 54-61.
Bayés A, Tsetsenis T, Ventura S, Avilés FX, Vendrell J, Sotiropoulou G. (2004) Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biological Chemistry 385: 517-524.
Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biology 25: 193-199.
Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, Sotiropoulou G, Sloane BF, Keppler D. (2004) Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23: 2206-2215.
Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP. (2003) Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 307: 948-955.
Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafeiropoulos N, Simillides G, Yiotakis A, Diamandis EP. (2003) Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncology Research 13: 381-391.
Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DHC, Diamandis EP. (2003) Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. Clinical Chemistry 49:77-86.
Gomis-Rüth FX, Bayés A, Sotiropoulou G, Pampalakis G, Tsetsenis T, Vigellas V, Avilés FX, and Coll M. (2002) The structure of prozyme unveils a novel activation mechanism for the human kallikrein family. The Journal of Biological Chemistry 277: 27273-27281.
Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson TJ, White JH. (2002) Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signalling on cell proliferation, differentiation, and immune system regulation. Molecular Endocrinology 16: 1243-1256.
Sotiropoulou G, Kono M, Anisowicz A, Stenman G, Tsuji S, Sager R. (2002) Identification and functional characterization of a human GalNAc a2,6-sialyltransferase with altered expression in breast cancer. Molecular Medicine 8: 42-55.
Zeeuwen PL, Van Vlijmen-Willems IM, Jansen BJ, Sotiropoulou G, Curfs JH, Meis JF, Janssen JJ, Van Ruissen F, Schalkwijk J. (2001) Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase. Journal of Investigative Dermatology 116: 693-701.
Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G. (2000) Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clinical Biochemistry 33: 369-375.
Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis P, Sotiropoulou G. (2000) Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rbeta). Journal of Immunological Methods 241: 83-95.
Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. (1999) Molecular characterization of zyme/protease M/neurosin, a hormonally-regulated kallikrein-like serine protease. Genomics 62: 251-259.
Anisowicz A, Sotiropoulou G, Sager R. (1999) Re-expression of the SPR1 gene in breast carcinomas by phorbol 12-myristate 13-acetate or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter. Molecular Medicine 5: 526-541.
Sotiropoulou G, Anisowicz A, Sager R. (1997) Identification, cloning and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. Journal of Biological Chemistry 272: 903-910.
Stenman G, Astrom AK, Roijer E, Sotiropoulou G, Zhang M, Sager R. (1997) Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence in situ hybridization. Cytogenetics and Cell Genetics 76: 45-46.
Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. (1996) A novel protease homolog diferentially expressed in breast and ovarian cancer. Molecular Medicine 2: 624-636.
Sotiropoulou G, Anisowicz A, Ryan K, Sager R. (1995) Isolation of a novel protease inhibitor involved in breast cancer and senescence». International Journal of Oncology Suppl. 7: 969.
Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Swisshelm K, Hendrix M, Thor A, Ryan K, Rafidi K, Seftor E. (1994) RNA genetics of breast cancer: maspin as a paradigm. Cold Spring Harbor Symposia of Quantitative Biology 59: 537-546.
Sager R, Anisowicz A, Neveu M, Liang P, Sotiropoulou G. (1993) Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. FASEB Journal 7: 964-970.

SELECTED PRESENTATIONS IN INTERNATIONAL SCIENTIFIC CONFERENCES

PATENTS

Hovnanian A, Sotiropoulou G, Pampalakis G, Furio L. (2014) "Methods and pharmaceutical compositions for the treatment of Netherton syndrome". Application Nr: EP14153629.2 (03 Feb 2014), Submission Number: 2562196 (filed, 2014)
Anisowicz A, Sager R, Sotiropoulou G. (1998) "Human protease M, a novel serine protease, and its cDNA sequence and diagnostic and therapeutic uses". PCT Int. Patent, WO 98/11238, 1-92.
Sotiropoulou G, Anisowicz A, Sager R. (1997) "Human cystatin M cDNA sequence, recombinant vector, gene regulation in tumor, and cancer diagnosis and therapy". PCT, WO 97/14797, 1-67.

SUBMISSIONS TO INTERNATIONAL DATABASE

Textbooks-Greek Editions

"Pharmaceutical Biotechnology. Fundamentals and Applications"
Daan JA Crommelin, Robert D Sindelar, Bernd Meibohm (Informa, 2008; 3rd Edition) Τίτλος Ελληνικής Έκδοσης: "Φαρμακευτική Βιοτεχνολογία. Βασικές Αρχές και Πρακτικές Εφαρμογές" Πανεπιστημιακές Εκδόσεις Παρισιάνου, 2011, A Tsiftsoglou, G Sotiropoulou

Editorial Group Member

"The Cell: A Molecular Approach" (5th Edition) Cooper GM, Hausman RE (Sinauer, 2009) Greek Edition: "To Κύτταρο: Μια Μοριακή Προσέγγιση" Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2011
"Molecular Biology of the Gene" (6th edition) James D Watson, Tania A Baker, Stephen P Bell, Alexander Gann, Michael Levine, Richard Losick (CSHLP, Pearson, Benjamin Cummings, Prentice Hall, 2008) Greek Edition: "Μοριακή Βιολογία του Γονιδίου" Utopia Publishing, 2010
"Recombinant DNA. Genes and Genomes – A Short Course" James Watson, Amy Caudy, Richard Myers, Jan Witkowski WH Freeman and Company, Cold Spring Harbour Laboratory Press (2007) Greek Edition: "Ανασυνδυασμένο DNA. Γονίδια και Γονιδιώματα - Μια Συνοπτική Παρουσίαση" Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2007

Handouts for Laboratory Training

G Sotiropoulou, I Zarkadis (Patras 2007) Laboratory Exercises for the Undergraduate Course "Pharmaceutical Biotechnology"
G Sotiropoulou, G Pampalakis (Patras 2010; 2006-2009 earlier versions) Laboratory Exercises for the Undergraduate Course "Molecular Biology-Genetics"

Distance Learning

Production of Alternative Teaching Material in HYPERTEXT format (EAP/GOU: KFE53) Topics: Cell division and cancer: Regulation of cell cycle, apoptosis, oncogenes, and tumor suppressor genes. Techniques and methodologies for analysis of mutations.

TEACHING

Undergraduate Courses:

Cell Biology (PHA-Y-124)
Pharmaceutical Biotechnology (PHA-Y-414)

Postgraduate Course:

Pharmaceutical Biotechnology (PST-F-104)

Recommended Textbooks:

Cell Biology

"Essential Cell Biology" by Alberts B, Bray D, Hopkin K, Johnson A, Lewis J, Raff M, Roberts K, Walter P. [Greek Edition: "Βασικές Αρχές Κυτταρικής Βιολογίας", Εκδόσεις ΠΑΣΧΑΛΙΔΗ, 2006]
"The Cell: A Molecular Approach" by Geoffrey M. Cooper and Robert Hausman, 5th Edition (2009) [Greek Edition: "Το Κύτταρο: Μια Μοριακή Προσέγγιση", Εκδόσεις Ι. ΜΠΑΣΔΡΑ, 2011]

Suggested Publications for Further Reading:

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011
Lord CJ, Ashworth A. Biology-driven cancer drug development: back to the future. BMC Biol 8: 38, 2010

Pharmaceutical Biotechnology

"Pharmaceutical Biotechnology. Fundamentals and Applications" by Daan J.A. Crommelin, Robert D. Sindelar, Bernd Meibohm, 3rd Edition, Informa Healthcare (2008)   [Greek Edition: "Φαρμακευτική Βιοτεχνολογία. Βασικές Αρχές και Πρακτικές Εφαρμογές", Εκδόσεις Παρισιάνου, 2011, Επιμέλεια Ελληνικής Έκδοσης: Αστέριος Σ. Τσιφτσόγλου και Γεωργία Σωτηροπούλου]

"Recombinant DNA. Genes and Genomes-A Short Course" by James Watson, Amy Caudy, Richard Myers, Jan Witkowski, W. H. Freeman and Company, Cold Spring Harbor Laboratory Press, 3rd Edition (2007) [Greek Edition: "Ανασυνδυασμένο DNA. Γονίδια και Γονιδιώματα - Μια Συνοπτική Παρουσίαση", Εκδόσεις Ι. ΜΠΑΣΔΡΑ, 2007]

"Pharmaceutical Biotechnology - Laboratory Exercises" by Sotiropoulou G, Zarkadis IK. Available in eclass

"PROTEOLYTIC ENZYMES" JBC THEMATIC MINIREVIEW SERIES (2009)